CN108779158B - 热稳定性fgf2多肽、其用途 - Google Patents

热稳定性fgf2多肽、其用途

Info

Publication number
CN108779158B
CN108779158B CN201680076784.3A CN201680076784A CN108779158B CN 108779158 B CN108779158 B CN 108779158B CN 201680076784 A CN201680076784 A CN 201680076784A CN 108779158 B CN108779158 B CN 108779158B
Authority
CN
China
Prior art keywords
fgf2
cells
polypeptide
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680076784.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108779158A (zh
Inventor
彼得·德沃夏克
帕维尔·克雷奇
卢卡斯·巴莱克
利维亚·艾塞利奥娃
赞尼塔·科尼卡
帕维尔·德沃夏克
戴维·贝德纳
简·布列佐夫斯基
伊娃·塞贝斯多瓦
拉德卡·查卢普科娃
维罗尼卡·斯蒂芬科娃
帕维尔·瓦纳塞克
茨比尼克·普罗科普
吉里·达姆博斯基
米歇尔·博萨科娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enantis S R O
MASARYK UNIVERSITY
Original Assignee
Enantis S R O
MASARYK UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enantis S R O, MASARYK UNIVERSITY filed Critical Enantis S R O
Publication of CN108779158A publication Critical patent/CN108779158A/zh
Application granted granted Critical
Publication of CN108779158B publication Critical patent/CN108779158B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
CN201680076784.3A 2015-11-27 2016-10-03 热稳定性fgf2多肽、其用途 Active CN108779158B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15196802.1 2015-11-27
EP15196802 2015-11-27
PCT/EP2016/073567 WO2017089016A1 (en) 2015-11-27 2016-10-03 Thermostable fgf2 polypeptide, use thereof

Publications (2)

Publication Number Publication Date
CN108779158A CN108779158A (zh) 2018-11-09
CN108779158B true CN108779158B (zh) 2026-05-01

Family

ID=54754475

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680076784.3A Active CN108779158B (zh) 2015-11-27 2016-10-03 热稳定性fgf2多肽、其用途

Country Status (12)

Country Link
US (1) US11746135B2 (enExample)
EP (1) EP3380508B1 (enExample)
JP (1) JP7131772B2 (enExample)
KR (1) KR102650035B1 (enExample)
CN (1) CN108779158B (enExample)
AU (1) AU2016359722B2 (enExample)
CA (1) CA3006388C (enExample)
ES (1) ES2824479T3 (enExample)
LT (1) LT3380508T (enExample)
PL (1) PL3380508T3 (enExample)
SG (1) SG11201804402WA (enExample)
WO (1) WO2017089016A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112190531B (zh) * 2019-06-19 2022-11-01 湖北医药学院 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法
CN115103903A (zh) * 2019-09-19 2022-09-23 西北大学 用于人诱导型多能干细胞的具成本效益的培养基和操作方案
US12103953B2 (en) 2019-11-25 2024-10-01 Korea Institute Of Ocean Science Technology FGF2 polypeptide with improved temperature stability and protease resistance and use thereof
KR102428940B1 (ko) * 2019-11-25 2022-08-03 한국해양과학기술원 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도
CZ309550B6 (cs) * 2021-06-15 2023-04-05 Enantis s.r.o Termostabilní polypeptid na bázi FGF18 a jeho použití
GB2616475A (en) * 2022-03-11 2023-09-13 Multus Biotechnology Ltd Engineered fibroblast growth factor variants
WO2024110932A1 (en) * 2022-11-25 2024-05-30 Btl Healthcare Technologies A.S. The fgf-2 polypeptides with improved stability, the process for preparing the fgf-2 polypeptides and use thereof
CN116041478A (zh) * 2022-12-19 2023-05-02 太东(镇江)生物科技有限公司 基于大肠杆菌体外纯化系统的人重组热稳定蛋白fgf2制备方法
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
KR102988516B1 (ko) * 2023-06-02 2026-07-09 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포의 배양방법
KR102988515B1 (ko) * 2023-06-02 2026-07-10 (주)피앤피바이오팜 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포 유래 엑소좀의 제조방법
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2025141173A1 (en) 2023-12-28 2025-07-03 Meatable B.V. Methods of increasing differentiation and/or fat accumulation in cells
WO2025186217A1 (en) 2024-03-05 2025-09-12 The Cultivated B. Gmbh Animal collagen from non-animal sources
EP4613865A1 (en) 2024-03-05 2025-09-10 The Cultivated B. GmbH Animal collagen from non-animal sources
WO2026093988A1 (en) * 2024-11-01 2026-05-07 Btl Healthcare Technologies A.S. The fgf-2 polypeptides with improved thermal and oxidative stability, the process for preparing the fgf-2 polypeptides and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008630A1 (en) * 1993-09-24 1995-03-30 American Cyanamid Company Surface loop structural analogues of fibroblast growth factors
CN103597076A (zh) * 2011-03-01 2014-02-19 人体酶公司 成纤维细胞生长因子的热稳定变体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU614137B2 (en) 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
US5202311A (en) 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
US5143829A (en) 1990-03-29 1992-09-01 California Biotechnology Inc. High level expression of basic fibroblast growth factor having a homogeneous n-terminus
AU6339198A (en) * 1997-02-26 1998-09-18 Ciblex Corporation Inhibitors of leaderless protein export
WO2002017956A2 (en) 2000-08-31 2002-03-07 Chiron Corporation Stabilized fgf formulations containing reducing agents
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1444995A1 (en) 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) FGF-2 derived proteins for the preparation of biomaterials or medical devices such as stents
US7816140B2 (en) 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
US20070212332A1 (en) 2005-08-11 2007-09-13 Department Of Veterans Affairs Methods for accelerating bone repair
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
US7659379B1 (en) 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
EP2333074A1 (en) * 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
US8481308B2 (en) 2010-07-01 2013-07-09 Regenerative Research Foundation Methods for culturing undifferentiated cells using sustained release compositions
WO2013082196A1 (en) 2011-11-28 2013-06-06 The Regents Of The University Of California bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF
WO2013090911A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Method for supporting human pluri potent stem cell cultures comprising culturing the cells in a medium comprising thermostable fgf - 1 proteins
WO2013090919A1 (en) 2011-12-16 2013-06-20 Wisconsin Alumni Research Foundation Fgf-2 having enhanced stability
US9474785B2 (en) * 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
EP2930181B1 (en) 2014-04-07 2017-10-11 Miltenyi Biotec GmbH Fibroblast growth factor muteins with increased activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008630A1 (en) * 1993-09-24 1995-03-30 American Cyanamid Company Surface loop structural analogues of fibroblast growth factors
CN103597076A (zh) * 2011-03-01 2014-02-19 人体酶公司 成纤维细胞生长因子的热稳定变体

Also Published As

Publication number Publication date
EP3380508B1 (en) 2020-07-22
JP7131772B2 (ja) 2022-09-06
CA3006388C (en) 2023-05-09
US20200270320A1 (en) 2020-08-27
EP3380508A1 (en) 2018-10-03
LT3380508T (lt) 2020-11-10
KR102650035B1 (ko) 2024-03-20
ES2824479T3 (es) 2021-05-12
BR112018010676A2 (pt) 2019-04-09
PL3380508T3 (pl) 2021-07-12
JP2019500414A (ja) 2019-01-10
WO2017089016A1 (en) 2017-06-01
CN108779158A (zh) 2018-11-09
US11746135B2 (en) 2023-09-05
SG11201804402WA (en) 2018-06-28
CA3006388A1 (en) 2017-06-01
AU2016359722B2 (en) 2020-09-17
KR20180080335A (ko) 2018-07-11

Similar Documents

Publication Publication Date Title
JP7131772B2 (ja) 熱安定性ｆｇｆ２ポリペプチド及びその使用
AU2016359722A1 (en) Thermostable FGF2 polypeptide, use thereof
Dvorak et al. Computer‐assisted engineering of hyperstable fibroblast growth factor 2
CN111454350B (zh) 一种重组纤连蛋白突变体及其应用
Logsdon et al. The IL-10R2 binding hot spot on IL-22 is located on the N-terminal helix and is dependent on N-linked glycosylation
Campbell et al. The solution structures of epidermal growth factor and transforming growth factor alpha
CN105420263B (zh) 重组人成纤维细胞生长因子-17的生产方法
CN116640204B (zh) 耐热纤连蛋白及其制备方法用途、核酸、表达载体及菌株
CN101967485A (zh) 人fgf21突变基因及制备重组人fgf21蛋白方法
Ye et al. An efficient large-scale refolding technique for recovering biologically active recombinant human FGF-21 from inclusion bodies
JP2014100141A (ja) 多能性幹細胞培養方法
Hecht et al. Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor-and heparin-binding interfaces
JP2017522052A (ja) ヒトＦＧＦＲ２ｃ細胞外ドメイン１４６−３５６とそれをコードする遺伝子及びそれらの応用
CN105176908B (zh) 一种重组人成纤维细胞生长因子(fgf)-18的生产方法
Niyogi et al. Evaluation of the role of electrostatic residues in human epidermal growth factor by site‐directed mutagenesis and chemical modification
CN107012150A (zh) 重组人成纤维细胞生长因子‑16的克隆、表达和应用及其生物学活性的测定方法
CN113583107B (zh) CRIg功能区蛋白变体及其应用
BR112018010676B1 (pt) Polipeptídeo termoestável e meio de cultura
CN100432107C (zh) 具有促红细胞生长因子活性的蛋白质及其用途
Hung et al. Functional characterization of ECP-heparin interaction: A novel molecular model
WO2021159205A1 (en) Chondroitinase abc mutants and methods of manufacture and use thereof
CN119192326B (zh) 重组cFGF2蛋白和鸟类原始生殖细胞培养基及其应用
CN111218452A (zh) 一种重组人tsg-6基因、重组人tsg-6蛋白标准品及其制备方法和应用
Liu et al. Computer-assisted engineering of stable human leukemia inhibitory factor
JP2024540542A (ja) 耐熱性ｆｇｆ１０ポリペプチド又はその断片，及びその使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant